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Objective: We sought to investigate the effect of α1-adrenoceptor activity on the
ischemic and reoxygenated human myocardium.
Methods: Right atrial appendages (n = 6 per group) obtained during elective cardiac
operations were sliced and stabilized in normoxic normothermic buffer solution for
30 minutes and then subjected to 90 minutes of simulated ischemia, followed by 120
minutes of reoxygenation. In study 1 the dose responses to the α1-adrenoceptor ago-
nist phenylephrine (0.01, 0.1, 1, 10, and 100 µmol/L) and to the α1-adrenoceptor
antagonist prazosin (0.1, 1, 10, and 100 µmol/L) when administered for 
10 minutes before ischemia, during ischemia, and during reoxygenation were exam-
ined. The influence of the time of administration (ie, before ischemia, during
ischemia, or during reoxygenation) of phenylephrine (0.1 µmol/L) and prazosin 
(10 µmol/L) was then investigated in study 2. In study 3 the effect of the combined
administration of phenylephrine given before ischemia and prazosin given during
ischemia was investigated. In study 4 the protective effect of phenylephrine given
before ischemia (for 10 minutes or for 5 minutes with a 5-minute washout period)
was compared with that of ischemic preconditioning (5 minutes of ischemia and 
5 minutes of reoxygenation). At the end of each protocol, the leakage of creatine
kinase (in units per gram of wet weight) and the reduction of 3-[4,5 dimethylthia-
zol-2-yl]-2,5 diphenyltetrazolium bromide to insoluble formazan dye (in millimoles
per gram of wet weight) were measured.
Results: Phenylephrine is maximally beneficial at 0.1 and 1 µmol/L (creatinine
kinase, 0.97 ± 0.06 and 0.95 ± 0.03 U/g, respectively; 3-[4,5 dimethylthiazol-2-yl]-
2,5 diphenyltetrazolium bromide, 153.0 ± 7.8 and 156.2 ± 6.7 mmol/g, respective-
ly) compared with ischemic control (creatine kinase, 1.87 ± 0.03 U/g; 3-[4,5
dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide, 108.5 ± 6.8 mmol/g; P <
.05) but prazosin is detrimental at concentrations above 10 µmol/L (creatine kinase,
5.22 ± 0.29 U/g; 3-[4,5 dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide,
69.8 ± 2.9 mmol/g; P < .05 vs ischemic control). In addition, phenylephrine (0.1
µmol/L) is protective when given before ischemia (creatine kinase, 2.06 ± 0.21 U/g;
3-[4,5 dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide, 148.5 ± 4.5 mmol/g;
P < .05 vs ischemic control) but is detrimental when given during ischemia alone
(creatine kinase, 4.49 ± 0.98 U/g; 3-[4,5 dimethylthiazol-2-yl]-2,5 diphenyltetra-
zolium bromide, 70.5 ± 6.1 mmol/g; P < .05 vs ischemic control) and has no sig-
nificant effect during reoxygenation. In contrast, prazosin (10 µmol/L) is beneficial
when given during ischemia alone (creatine kinase, 1.34 ± 0.10 U/g; 3-[4,5
dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide, 148.5 ± 4.5 mmol/g; 
P < .05 vs ischemic control), is detrimental when given during reoxygenation alone
(creatine kinase, 1.5 ± 0.16 U/g; 3-[4,5 dimethylthiazol-2-yl]-2,5 diphenyltetrazoli-
um bromide, 85.0 ± 4.7 mmol/g; P < .05 vs ischemic control), and has no effect
when given before ischemia. The use of phenylephrine before ischemia alone is as
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Activation of α1-adrenoceptors induces pos-itive inotropic, chronotropic, and dro-motropic actions in the heart and vasculareffects1-4 that are clinically exploited tooptimize hemodynamic conditions. How-ever, it is generally believed that activation
of α1-adrenoceptors is detrimental to the ischemic heart, a
thesis that would be supported by the increased release of
cardiac and plasma catecholamines5 and the enhanced densi-
ty of cardiac α1-adrenoceptors during ischemia.6-8 However,
it has recently been shown that α1-adrenoceptors mediate the
protection induced by ischemic preconditioning in animals
and in the human myocardium9-14 by means of phospholi-
pase C and protein kinase C activation,13 and this has given
rise to the possibility that the effect of α1-adrenoceptors in
ischemic injury may depend on the dose and the time of
their activation (ie, before, during, or after ischemia). To
investigate this, right atrial appendages were obtained from
patients undergoing elective coronary bypass operations,
and the muscles were subjected to various protocols in a val-
idated in vitro model of simulated ischemia and reoxygena-
tion.15
Methods
Experimental Preparation
Experiments were performed on myocardium obtained from the
right atrial appendage of patients undergoing elective coronary
artery operations or aortic valve replacement in a cell necrosis
model that was developed in our laboratory and described previ-
ously.15 Patients were excluded if they had enlarged atriums, atrial
arrhythmias, poor left ventricular function (ejection fraction,
<30%), and right ventricular failure or were taking oral hypo-
glycemic agents, opioid analgesics, KATP channel openers, or cat-
echolamines. Local ethical committee approval was obtained for
the harvesting technique. The specimens were collected in oxy-
genated N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid–
buffered solution at 4°C to 5°C and immediately sectioned and
prepared for study. The appendage was mounted onto a ground
glass plate with the epicardial surface face down and then sliced
freehand with surgical skin graft blades (Shwann-Morton) to a
thickness of between 300 and 500 µm. The specimen and the slide
were always kept moist throughout the procedure. The muscles
(weight 30-50 mg) were then transferred to conical flasks (25-mL
Erlenmeyer flasks, Schott Glaswerk) containing 10 mL of oxy-
genated buffered solution, and the flasks were placed in a shaking
water bath maintained at 37°C. The oxygenation of the incubation
medium was maintained by a continuous flow of 95% O2/5% CO2
gas mixture to obtain a PO2 of between 185 and 225 mm Hg and a
PCO2 of between 45 and 50 mm Hg. The PO2, PCO2, and pH in the
incubation medium were monitored by means of intermittent
analyses of the effluent with an automated blood gas analyzer
(model 855 Blood Gas System, Chiron Diagnostics), and the pH
was kept between 7.36 and 7.45. For the induction of simulated
ischemia, the medium was bubbled with 95% N2/5% CO2 (pH
6.80-7.00), and D-glucose was replaced with 2-deoxyglucose. In
this preparation creatine kinase (CK) leakage (in units per gram of
wet weight) was taken as a measure of tissue injury, and the reduc-
tion of 3-[4,5 dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bro-
mide (MTT) to an insoluble formazan dye (in millimoles per gram
of wet weight) was used to assess tissue viability. The atrial tissue
was not paced, and the force developed was not measured in these
studies.
Solutions and Drugs
The incubation medium was prepared daily with deionized distilled
water and contained the following: NaCl2, 118 mmol/L; KCl, 4.8
mmol/L; NaHCO3, 27.2 mmol/L; MgCl2, 1.2 mmol/L; KH2PO4, 1.0
mmol/L; CaCl2, 1.25 mmol/L; D-glucose, 10 mmol/L; and N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic acid, 20 mmol/L. As
mentioned above, during simulated ischemia, D-glucose was
removed and substituted with 2-deoxyglucose (10 mmol/L) to main-
tain a constant osmolarity. Phenylephrine and prazosin were dis-
solved in deionized distilled water immediately before their use. All
reagents were obtained from Sigma.
Experimental Protocols
After sectioning the atrium, the preparations were allowed to sta-
bilize for 30 minutes and then randomly allocated to various pro-
tocols. In all the studies, simulated ischemia was induced for a
period of 90 minutes, followed by 120 minutes of reoxygenation.
Some of the preparations were not made ischemic and instead were
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protective as prazosin given during ischemia alone, but the combination of the two
drugs does not cause additional benefit. Interestingly, the protection afforded by
phenylephrine when given before ischemia is similar to that obtained with ischemic
preconditioning.
Conclusions: In the human myocardium activation of α1-adrenoceptors before
ischemia is protective but is detrimental during ischemia, whereas blockade of α1-
adrenoceptors is beneficial during ischemia but detrimental during reoxygenation. The
degree of protection achieved by activation of the α1-adrenoceptors before ischemia
is similar to that obtained with blockade of α1-adrenoceptors during ischemia and that
of ischemic preconditioning. 
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aerobically perfused for 240 minutes to serve as aerobic matched
controls.
Study 1: Dose response to phenylephrine and prazosin. In this
study various concentrations of the α1-adrenoceptor agonist
phenylephrine (0.01, 0.1, 1, 10, and 100 µmol/L) and the α1-
adrenoceptor antagonist prazosin (0.1, 1, 10, and 100 µmol/L)
were added to the incubation media for 10 minutes before
ischemia, during ischemia, and during reoxygenation (n = 6 prepa-
rations per group).
Study 2: Influence of the time of administration of phenyl-
ephrine and prazosin. Influence of phenylephrine (0.1 µmol/L)
and prazosin (10 µmol/L) was investigated by the exposure of the
myocardial tissue to the optimal concentrations of the drugs shown
in study 1 for 10 minutes before ischemia, during ischemia, and
during reoxygenation alone and in combination (n = 6 preparations
per group).
Study 3: Potency of phenylephrine- and prazosin-induced
protection. The most beneficial dose and time of administration
for phenylephrine and prazosin seen in the 2 previous studies were
used alone and in combination (n = 6 preparations per group) to
study the potency of the protection offered by the drugs.
Study 4: Phenylephrine and ischemic preconditioning. To
investigate the potency of protection of the α1-agonist phenyl-
ephrine compared with that of ischemic preconditioning, right atri-
al specimens (n = 6 per group) were subjected to a protocol of
ischemia-reoxygenation identical to the one used in the previous
studies. Phenylephrine at a concentration of 0.1 µmol/L was used
before ischemia for 10 minutes or for 5 minutes followed by 
5-minute washout period. Ischemic preconditioning was induced
by 5 minutes of ischemia and 5 minutes of reoxygenation immedi-
ately before the 90-minute ischemia, a protocol shown to afford
maximal protection in this preparation.16
Figure 1. CK leakage (A) and MTT reduction (B) of human right atrial myocardium subjected to 90 minutes of
ischemia and 120 minutes of reoxygenation and incubated with various concentrations of phenylephrine. The drug
was present in the incubation media for 10 minutes before the induction of ischemia, during ischemia, and during
reoxygenation. Columns represent the mean of 6 experiments, and bars represent the SEM. *P < .05 versus
phenylephrine-free group.
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Assessment of Tissue Injury and Viability
Tissue injury was determined by measuring the leakage of CK into
the incubation medium during the 120-minute reoxygenation peri-
od. This was assayed by means of a kinetic UV method based on
the formation of NAD (Sigma Catalogue No. 1340-K), and the
results were expressed as units per gram of wet weight.
Tissue viability was assessed by the reduction of MTT to a blue
formazan product at the end of the experimental period. The tissue
was loaded into a Falcon conical tube (15 mL, Becton Dickinson
Labware) into which 2 mL of phosphate buffer solution (0.05 mol/L)
containing MTT (1.25 mg/mL; 3 mmol/L at final concentration) was
added and then incubated for 30 minutes at 37°C. After this, the tis-
sue was homogenized in 2 mL of dimethylsulfoxide (Homogenizer
Ultra-Turrax T25, dispersing tool G8, IKA-Labortechnic) at 9500
rpm for 1 minute. The homogenate was then centrifuged at 1000g
for 10 minutes, and 0.2 mL of the supernatant was dispensed into a
98-well flat-bottom microtiter plate (Nunc Brand Products). After
this, the absorbance of the blue formazan formed was measured on
a plate reader (Benchmark, Bio-Rad Laboratories) at 550 nm, and
the results were expressed as millimoles per gram of wet weight.
Statistical Analysis
All data are presented as means ± SEM. Analysis of variance was used
for multiple comparisons, with application of a post hoc Tukey test.
Results 
Study 1: Dose Response to Phenylephrine and Prazosin
The results shown in Figure 1, A and B, on CK leakage and
MTT reduction demonstrate that phenylephrine induces a
dose-response curve with maximal protection at 0.1 and 
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Figure 2. CK leakage (A) and MTT reduction (B) of human right atrial myocardium subjected to 90 minutes of ischemia
and 120 minutes of reoxygenation and incubated with various concentrations of prazosin. The drug was present in
the incubation media for 10 minutes before the induction of ischemia, during ischemia, and during reoxygenation.
Columns represent the mean of 6 experiments, and bars represent the SEM. *P < .05 versus prazosin-free group.
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1 µmol/L and a loss of protection at doses of 10 µmol/L and
greater. It is important to note that although protection was
lost at the highest concentrations of phenylephrine, higher
doses did not exert a detrimental effect, and therefore CK
leakage and MTT mean values were similar to those seen in
the phenylephrine-free group.
As seen in Figure 2, A and B, CK leakage and MTT
reduction were not significantly affected by prazosin when
present in the incubation media throughout the experiment
at the lowest concentrations of 0.1 and 1 µmol/L. However,
in contrast with the results for phenylephrine, prazosin was
detrimental at the highest concentrations (10 and 100
µmol/L), as shown by the significant increase in CK leakage
and a decrease in MTT reduction.
Study 2: Influence of the Time of Administration of
Phenylephrine and Prazosin
Figure 3, A and B, shows the results of phenylephrine when
given at different times at a chosen concentration of 0.1
µmol/L, which was shown to be the most effective dose in
study 1. These results demonstrate, in terms of both CK
leakage and MTT reduction, that maximal protection was
obtained when phenylephrine was administered before
ischemia alone, an effect that was equivalent to the one
obtained with phenylephrine throughout the entire experi-
mental period. Phenylephrine given during the reoxygena-
tion period alone was less protective than when given before
ischemia, and this was reflected by a modest but significant
decrease in CK leakage without affecting MTT reduction.
Figure 3. CK leakage (A) and MTT reduction (B) of human right atrial myocardium subjected to 90 minutes of
ischemia and 120 minutes of reoxygenation and incubated with 0.1 µmol/L phenylephrine for different times.
Columns represent the mean of 6 experiments, and bars represent the SEM. *P < .05 versus the phenylephrine-free
group.
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Interestingly, the administration of phenylephrine during
ischemia alone was detrimental, as seen by the significant
decrease in MTT reduction. It is worth noting that the
adverse effect of phenylephrine during ischemia was com-
pletely counteracted when the drug was also present before
ischemia and during reoxygenation.
Figure 4, A and B, shows the results on CK leakage and
MTT reduction for prazosin given at various times at a
concentration of 10 µmol/L. These results show that pra-
zosin did not have a significant effect when given before
ischemia alone, that it was detrimental when given during
reoxygenation alone to a degree similar to the administra-
tion of prazosin during the entire experimental period, and
that it was protective when given during ischemia alone.
Importantly, the beneficial action of prazosin during
ischemia was abolished when the drug was present before
ischemia.
Study 3: Potency of Phenylephrine- and Prazosin-
Induced Protection
As indicated by the results on CK leakage and MTT reduc-
tion shown in Figure 5, A and B, phenylephrine given before
ischemia alone and prazosin given during ischemia alone
afforded similar protection, and the combination of the two
did not result in greater protection than that obtained with
each drug given alone.
Cardiopulmonary Support and Physiology Loubani and Galiñanes
Figure 4. CK leakage (A) and MTT reduction (B) of human right atrial myocardium subjected to 90 minutes of
ischemia and 120 minutes of reoxygenation and incubated with 10 µmol/L prazosin for different times. Columns
represent the mean of 6 experiments, and bars represent the SEM. *P < .05 versus the prazosin-free group.
A
B
Loubani and Galiñanes Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery • Volume 122, Number 1 109
TX
ET
CS
P
CP
S
CH
D
G
TS
ED
IT
O
RI
A
L
Study 4: Phenylephrine and Ischemic Preconditioning
Figure 6, A and B, shows that ischemic preconditioning
induces a significant decrease in CK leakage and better pre-
serves MTT reduction when compared with the effects seen
in muscles subjected to ischemia-reoxygenation alone. The
results confirm previous findings from our laboratory using
an identical preparation and protocol.16 They also show that
the α1-agonist phenylephrine given for 10 minutes before
ischemia or for 5 minutes with a 5-minute washout period
before ischemia, thus mimicking the ischemic precondition-
ing protocol, results in similar protection to that seen with
ischemic preconditioning.
Discussion
The present study has demonstrated that α1-adrenoceptors
play an important role in the ischemia-reoxygenation–
induced injury of the human atrial myocardium. Thus they
show that stimulation of α1-adrenoceptors with phenyl-
ephrine protects against injury, whereas α1-adrenoceptor
blockade with prazosin is detrimental; both effects are
Figure 5. CK leakage (A) and MTT reduction (B) of human right atrial myocardium subjected to 90 minutes of
ischemia and 120 minutes of reoxygenation and incubated with phenylephrine (0.1 µmol/L) for 10 minutes before
ischemia, with prazosin (10 µmol/L) during ischemia, and with the 2 drugs in combination. Columns represent the
mean of 6 experiments, and bars represent the SEM. *P < .05 versus the group with ischemia-reoxygenation (I/R)
alone.
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obtained in a dose-dependent manner. They have also shown
that the effect of the stimulation or blockade of α1-adreno-
ceptors depends on the time of administration so that α1-
adrenoceptor stimulation is protective when given before
ischemia but detrimental when given during ischemia. On
the contrary, α1-adrenoceptor blockade is beneficial during
ischemia and detrimental during reoxygenation and has no
significant effect before ischemia. It appears that similar
maximal protection can be obtained with α1-adrenoceptor
stimulation before ischemia and with α1-adrenoceptor
blockade during ischemia, although the combination of the
two does not induce additional protection. Furthermore, the
protective effect of α1-adrenoceptor stimulation before
ischemia is as potent as ischemic preconditioning. These
studies are the first in dissecting the role of α1-adrenocep-
tors during ischemia and reoxygenation of the human
myocardium, and the results have important mechanistic
and clinical implications that warrant further discussion.
Our results showing that α1-adrenoceptor activation
before ischemia is cardioprotective are in agreement with
the observation of other investigators that α1-adrenoceptors
participate in the protection induced by ischemic precondi-
tioning in the rat heart9,17 and in the human myocardium.13
However, it is worth noting that although α1-adrenoceptor
Cardiopulmonary Support and Physiology Loubani and Galiñanes
Figure 6. CK leakage (A) and MTT reduction (B) of human right atrial myocardium subjected to 90 minutes of
ischemia and 120 minutes of reoxygenation after ischemic preconditioning (5 minutes of ischemia and 5 minutes
of reoxygenation) or incubation with phenylephrine (0.1 µmol/L) for 10 minutes or for 5 minutes with a 5-minute
washout period. Columns represent the mean of 6 experiments, and bars represent the SEM. *P < .05 versus the
group with ischemia-reoxygenation (I/R) alone.
A
B
Loubani and Galiñanes Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery • Volume 122, Number 1 111
TX
ET
CS
P
CP
S
CH
D
G
TS
ED
IT
O
RI
A
L
stimulation mimicked the protection of ischemic precondi-
tioning in our studies, protection was less and did not repli-
cate that obtained with ischemic preconditioning in the
study of Cleveland and colleagues,13 who also used the human
myocardium. Certainly, there are differences in the experi-
mental model and the doses of the α1-adrenoceptor agonist
phenylephrine used in the 2 studies that may explain the dif-
fering results. Thus our studies were carried out in a model
of necrosis in which muscles were not electrically stimulat-
ed and were subjected to 90 minutes of simulated ischemia,
whereas in the study of Cleveland and colleagues,13 the
muscles were stimulated, and functional recovery, as
opposed to necrosis, was assessed after only 45 minutes of
ischemia. Furthermore, our dose-response study with
phenylephrine showed that there is a bell-shaped response,
with maximal protection at concentrations of 0.1 and 1
µmol/L and loss of protection at concentrations of 10
µmol/L or greater, as used in their study.13 It is of interest
that similar protection was obtained with phenylephrine
administered for 10 minutes immediately before ischemia
or for only 5 minutes with a 5-minute washout period before
ischemia, thus suggesting that a short period of stimulation
of α1-adrenoceptors is sufficient to attain maximal benefit.
The harmful effect seen when α1-adrenoceptors were
activated only during ischemia and the protection obtained
with their blockade were not unexpected and are supported
by the reported literature.18,19 However, an important con-
tribution of the present study is that the activation of α1-
adrenoceptors during ischemia does not diminish the pro-
tection induced by the activation of these receptors before
ischemia. It was also important that the protection seen with
α1-adrenoceptor blockade during ischemia is lost when the
blockade is continued during reoxygenation. These results
contradict the never-confirmed assumption that activation of
α1-adrenoceptors during reoxygenation may extend reper-
fusion injury.20 In fact, they show that activation of α1-
adrenoceptors during reoxygenation does not significantly
influence myocardial injury and that, on the contrary, α1-
adrenoceptor blockade augments injury.
Although the signal transduction pathways that follow the
activation of α1-adrenoceptors are well described,21-33 the pre-
cise mechanisms responsible for their opposing actions in
ischemia-reoxygenation remain unclear. It is possible that the
increase in cytosolic calcium levels induced by α1-adrenocep-
tor agonists through cyclic adenosine monophosphate19 may
mediate the effects discussed above. Indeed, calcium overload
can be harmful when occurring during ischemia,34 and it may
precondition the heart and be protective35,36 when it occurs
before ischemia. The demonstration by Miyawaki and
Ashraf37 that a transient increase in cytosolic calcium levels
during ischemic preconditioning is an important trigger for the
activation and translocation of the protein kinase C isoforms α
and δ further supports this hypothesis.
The binding of agonists to α1-adrenoceptors also causes the
activation of phospholipase C, and this hydrolyzes 
phosphatidylinositol-4,5-biphosphate, resulting in the produc-
tion of inositol-1,4,5-triphosphate and 1,2-diacylglycerol.21,22
Inositol-1,4,5-triphosphate acts on the sarcoplasmic reticu-
lum, increasing intracellular calcium levels,23,24 whereas
1,2-diacylglycerol activates protein kinase C,25 which in
turn activates the transsarcolemal voltage-dependent calci-
um channels26-29 and  the Na+/H+ channels30 and the open-
ing of mitochondrial KATP channels.31 There is evidence that
stimulation of α1-adrenoceptors through activation of protein
kinase C also enhances 5´-nucleotidase activity and hence
adenosine formation,32 which has been shown to influence the
outcome of myocardial ischemia-reperfusion in a number of
experimental models and species.33,38,39 To what extent each
of these mechanisms is participating in the action of α1-
adrenoceptors during ischemia and reoxygenation is unclear;
however, from our studies, it is evident that the result of the
use of agents that activate or blockade these receptors may
vary widely depending on time of initiation and termination
of administration, and it is possible that more than one
mechanism may be involved. Clearly, more studies are
needed to elucidate the underlying mechanism of these
actions.
A possible limitation of the present study is the use of atri-
al tissue as opposed to ventricular tissue, and therefore any
extrapolation should be made with caution. Another possible
limitation might be that right atrial appendages were obtained
from patients taking antianginal medication, and this poten-
tially may have had some influence on the ischemia-
reoxygenation injury. Furthermore, our studies were per-
formed in an in vitro preparation, and therefore the clinical
application of the results should also be made with caution.
Despite the above potential shortcomings, the findings of
our study may have important therapeutic implications for
myocardial protection during cardiac operations, cardiac
transplantation, angioplasty, and acute myocardial infarc-
tion, for which agents acting on α1-adrenoceptors are fre-
quently used. Particular attention must be paid during car-
diac operations in which phenylephrine is used routinely to
elevate the mean arterial blood pressure during cardiopul-
monary bypass, and in doing so, one may be unwittingly
exacerbating myocardial injury during cardiac ischemia,
when collateral blood flow enters the ischemic myocardi-
um. However, these studies have shown that such undesir-
able effects can be fully counteracted by the administration
of phenylephrine before the induction of cardiac ischemia.
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